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Abstract
We reviewed technical parameters, acquisition protocols and adverse reactions (ARs) for contrast-enhanced spectral
mammography (CESM). A systematic search in databases, including MEDLINE/EMBASE, was performed to extract
publication year, country of origin, study design; patients; mammography unit/vendor, radiation dose, low-/high-
energy tube voltage; contrast molecule, concentration and dose; injection modality, ARs and acquisition delay;
order of views; examination time. Of 120 retrieved articles, 84 were included from 22 countries (September 2003–
January 2019), totalling 14012 patients. Design was prospective in 44/84 studies (52%); in 70/84 articles (83%), a
General Electric unit with factory-set kVp was used. Per-view average glandular dose, reported in 12/84 studies
(14%), ranged 0.43–2.65 mGy. Contrast type/concentration was reported in 79/84 studies (94%), with Iohexol
350 mgI/mL mostly used (25/79, 32%), dose and flow rate in 72/84 (86%), with 1.5 mL/kg dose at 3 mL/s in 62/72
studies (86%). Injection was described in 69/84 articles (82%), automated in 59/69 (85%), manual in 10/69 (15%) and
flush in 35/84 (42%), with 10–30 mL dose in 19/35 (54%). An examination time < 10 min was reported in 65/84
studies (77%), 120 s acquisition delay in 65/84 (77%) and order of views in 42/84 (50%) studies, beginning with the
craniocaudal view of the non-suspected breast in 7/42 (17%). Thirty ARs were reported by 14/84 (17%) studies (26
mild, 3 moderate, 1 severe non-fatal) with a pooled rate of 0.82% (fixed-effect model). Only half of CESM studies
were prospective; factory-set kVp, contrast 1.5 mL/kg at 3 mL/s and 120 s acquisition delay were mostly used; only 1
severe AR was reported. CESM protocol standardisation is advisable.
Keywords: Breast, Contrast media, Drug-related side effects and adverse reactions, Mammography, Radiation
dosage
Key points
 Eighty-four articles on CESM totalling 14012
patients were reviewed
 A 1.5 mL/kg contrast dose automatically injected at
3 mL/s was generally adopted
 Per-view average glandular dose ranged from 0.43 to
2.65 mGy
 Studies for contrast agent dose-finding and view
acquisition ordering are lacking
 Adverse reaction rate (only one severe) was similar
to that reported for CT
Background
During the 1960s and 1970s, randomised controlled tri-
als proved that screen-film mammography for breast
cancer screening yields a reduction in breast cancer
mortality [1]. Since the early 2000s, screen-film mam-
mography was progressively replaced by digital mam-
mography (DM), which improved performance
especially in women under 50 years of age and in case of
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
* Correspondence: andrea.cozzi1@unimi.it
1Department of Biomedical Sciences for Health, Università degli Studi di
Milano, Via Mangiagalli 31, 20133 Milan, Italy
Full list of author information is available at the end of the article
Insights into ImagingZanardo et al. Insights into Imaging           (2019) 10:76 
https://doi.org/10.1186/s13244-019-0756-0
dense breasts, even though providing an intrinsically in-
ferior spatial resolution [2]. In the last two decades,
digital breast tomosynthesis brought substantial further
improvements [3, 4], increasing cancer detection rate
and reducing the recall rate [5].
Contrast-enhanced mammography is the combin-
ation of X-ray mammography with intravenous ad-
ministration of iodinated contrast agent (ICA) [6]. It
was first attempted using a digital subtraction tech-
nique [7–9], but this approach was soon abandoned
due to difficulties in co-registration of unenhanced
and contrast-enhanced images [10, 11]. In the last
two decades, contrast-enhanced spectral mammog-
raphy (CESM) has been introduced, based on dual-
energy breast exposure (about 26–33 kVp and 44–
50 kVp) after contrast administration, so that the pre-
contrast exposure was no longer needed [10, 12].
CESM allows for the visualisation of enhancing find-
ings over the normal unenhancing breast tissue,
exploiting the increased contrast uptake of malignan-
cies [6, 10, 13].
Original studies have investigated the use of CESM in a
number of settings, such as evaluation of symptomatic
women [14–17], screening recalls [18–22], local staging
[23–32], pre- and post-operative evaluations [23, 24, 33–36]
and neoadjuvant chemotherapy response monitoring [37–
40]. In 2016, a first meta-analysis on CESM described a high
pooled sensitivity (98%) albeit with a relatively low specificity
(58%) [41], the latter partly caused by inexperience. A more
recent meta-analysis [42] reported globally satisfying data
for CESM-pooled sensitivity (89%) and specificity (84%),
proposing it as an alternative to contrast-enhanced magnetic
resonance imaging (MRI) and even suggesting CESM as a
“useful triage test for initial breast lesions assessment” [41].
A time delay between the first appearance of new
imaging techniques and their implementation in diag-
nostic routine is expected for many reasons, including
not only the definition of indications but also the re-
producibility of results. The latter is strongly influ-
enced by technique details, such as contrast agent
concentration, dose and injection rate, breast com-
pression and positioning, exposure parameters and ac-
quisition protocol. Indeed, the fact that CESM is
variably performed across different centres, without
an agreed and standardised technique, does not come
as a surprise: this circumstance echoes the one ob-
served for contrast-enhanced breast MRI in the
1990s, now settled by the publication of detailed
international guidelines [43–46].
Therefore, the aim of this work was to review
CESM studies focusing on adopted technique, con-
trast agent issues and acquisition workflow. This ef-
fort is crucial for future CESM investigations to be
reproducible and comparable.
Methods
Study protocol
No ethics committee approval was needed for this sys-
tematic review. The study protocol was registered on
PROSPERO (protocol CRD42018118554), the inter-
national prospective register of systematic reviews [47].
This systematic review was reported according to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement [48].
Search strategy and eligibility criteria
In February 2019, a systematic search was performed on
MEDLINE (PubMed, https://www.ncbi.nlm.nih.gov/
pubmed/), EMBASE (Elsevier), the Cochrane Library
(Cochrane Database of Systematic Reviews) and
the Cochrane Central Register of Controlled Trials for
articles that reported or may have reported CESM tech-
nique. A controlled vocabulary (medical subject headings
in PubMed and EMBASE thesaurus keywords in
EMBASE) was used. The search string was (cesm OR
‘contrast enhanced spectral mammography’/exp. OR
‘dual energy mammography’ OR ‘contrast enhanced
digital mammography’/exp. OR ‘contrast-enhanced
mammography’ OR ‘dual-energy subtraction mammog-
raphy’ OR cedm OR cedsm OR ‘contrast enhanced spec-
tral imaging’ OR ‘high energy and low energy digital
mammography’) AND (‘procedures’/exp. OR ‘method’
OR ‘methods’ OR ‘procedure’ OR ‘procedures’ OR ‘tech-
nique’ OR ‘acquisition’/exp. OR ‘contrast medium’/exp.
OR ‘contrast agent’ OR ‘contrast dye’ OR ‘contrast ma-
terial’ OR ‘contrast media’ OR ‘contrast medium’ OR
‘radiocontrast medium’ OR ‘radiography contrast
medium’ OR ‘roentgen contrast medium’ OR ‘image
processing’/exp. OR ‘image processing’ OR ‘image pro-
cessing, computer-assisted’ OR ‘processing, image’).
The search was limited to original studies on humans
published in English, French and Spanish on peer-
reviewed journals, with an available abstract. No publica-
tion date limits were applied. First article screening was
performed by two independent readers (A.C. and M.Z.,
with 1- and 3-year experience in breast imaging, respect-
ively) considering only title and abstract. Eligible articles
were those that reported in the title or in the abstract
the use of CESM technique or that could have contained
these data in the manuscript. After downloading eligible
articles, the full text was read for a complete assessment.
Finally, references of included articles were hand-
searched to check for further eligible studies.
Data extraction
Data extraction was performed independently by the
same two readers who performed the literature search.
Disagreements were settled by consensus. For each ana-
lysed article, year of publication, institution (such as
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hospitals, imaging facilities, breast units including radi-
ology sections or any other type of centre in which
CESM is performed) and country origin as well as re-
search groups, design, number of patients and demo-
graphics were retrieved. Mammography unit, vendor,
radiation dose and technical features such as low- and
high-energy peak kilovoltage (kVp), anode/filter combi-
nations and exposure parameters were also extracted.
Moreover, contrast agent type, dose and concentration
were retrieved, as well as injection modality, if manual
or automated, flow rate and additional post-contrast sa-
line flush or “bolus chaser” if present. Furthermore,
mild, moderate or severe adverse reactions to ICAs were
extracted alongside strategies for their prevention. Re-
garding the acquisition protocol, time between contrast
injection and first image acquisition and maximum
examination duration were extracted. Regarding the
order of views, we reported the acquisition sequence of
the standard mammographic projections considering the
craniocaudal (CC) and the mediolateral oblique (MLO)
views, including the first side acquired. Missing data
were requested to authors.
Evidence synthesis
To avoid risk of data duplication bias, in case of articles
published by the same research group, we considered
the possibility of performing subgroup analysis: there-
fore, before delving into further analysis of protocol de-
scription, we chose to change our viewpoint from the
number of articles reporting a specific protocol to the
minimum number of times a protocol was reported by a
single research group.
Regarding the pooled rate of adverse reactions related
to ICA administration across studies, statistical analysis
was performed using Comprehensive Meta-Analysis
v2.2.057 (Biostat, Englewood, NJ, USA) using the meta-
analysis model “Number of events and study popula-
tion”. I2 statistics was first calculated to assess hetero-
geneity and the fixed-effect model was used to provide
the rate of adverse reactions and 95% of confidence in-
tervals (CI). The risk of publication bias was assessed by
visually inspecting funnel plot and performing the Egger
test [49].
Results
Studies
A flowchart of study selection is shown in Fig. 1. Of 120
retrieved articles, 84 (70%), published between Septem-
ber 2003 and January 2019, were analysed [7–10, 13–40,
50–101]; 40/84 (48%) being retrospective and 44/84
(52%) prospective (43/44 monocentric (98%) and 1/44
multicentric (2%); 54/84 (64%) articles investigated
CESM diagnostic performance, whereas 30/84 (36%)
focused on technical features. The geographic distribu-
tion of research groups is depicted in Fig. 2.
Populations and settings
Data synthesis is reported in Table 1. The number of
patients ranged from 5 [63] to 2303 [13], for a total of
14,012 patients, with mean or median age ranging from
45 years [40] to 66 years [23]. In 29/84 studies (35%), CESM
was performed on patients from comprehensive databases
of heterogeneous settings, such as pre- or post-operative
evaluation, adjuvant or neoadjuvant chemotherapy re-
sponse monitoring and equivocal findings at conventional
imaging. The remaining 55 studies (65%) were individually
centred on a unique setting. Twenty-seven studies (32%)
performed CESM on suspicious cases from conventional
imaging and screening recalls, 11 studies (13%) in a first-
line screening setting, 7 (8%) performed CESM exclusively
for known cancer staging, 4 (5%) in a pre-operative setting,
4 (5%) to assess and monitor the response to adjuvant
chemotherapy and 2 (2%) in a post-operative setting.
Timing of CESM examination with menstrual cycle
was reported only in 18/84 studies (21%). In 10/18 (56%)
articles, it was mentioned but not applied; in 6/18 (33%),
it was applied with a feasibility window between the 5th
and 14th day of menstrual cycle; in 2/18 (11%), CESM
was synchronously performed with MRI in different
phases of menstrual cycle to evaluate and compare back-
ground parenchymal enhancement.
Technical features and parameters
In 70 out of 84 studies (83%), different systems from
General Electric Healthcare (Chicago, IL, USA) were
used, all with a prototype or a commercial release of the
SenoBright upgrade which is required to perform dual-
energy contrast-enhanced imaging. Twelve out of 84
articles (14%) reported the adoption of Selenia Dimen-
sions Mammography Unit (Hologic Inc., Marlborough,
MA, USA), while the remaining 2/84 (3%) studies were
conducted with a Siemens Healthineers (Erlangen,
Germany) Mammography System (Mammomat or
Mammomat Inspiration).
The type of ICA used was not reported in five articles
[15, 24, 64, 66, 75], while in the remaining 79 studies
(94%), for a total of 13465 patients (96%), six different
molecules were used: Iohexol was the most frequently
employed, being used in 42/79 studies (53%) for a total
of 5049/13465 patients (37%), followed by Iopromide
(18/79 studies, 23%; 2798/13465 patients, 21%), while
Iobitridol, Iomeprol, Iopamidol and Ioversol were admin-
istered in the remaining studies (19/79 studies, 24%; 5618/
13465 patients, 42%). Iohexol was utilised at a concentra-
tion of 350mg iodine/mL (25/42 studies, 60%; 3330/5049
patients, 66%) or 300mg iodine/mL (17/42 studies, 40%;
1719/5049 patients, 34%). Iopromide was also
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administered at two different concentrations: 370mg iod-
ine/mL (10/18 studies, 56%; 1032/2798 patients, 37%)
and 300 mg iodine/mL (8/18 studies, 44%; 1766/2798
patients, 63%).
Of the 69 studies including a specification of the con-
trast injection modality, 59 (85%) utilised an automated
power injector (10584/11725 patients, 90%) while man-
ual contrast injection was carried out in the remaining
10 (15%) [7, 9, 17, 25, 28, 51, 57, 73, 95, 99] for a total of
1141/11725 patients (10%).
Contrast agent dose, detailed in 77 studies, was fixed at
1.5mL/kg in 72 (93%) of them for a total of 13559/13687
(99%) patients. Contrast agent flow rate, reported in 76/84
studies (90%), was most frequently fixed at 3mL/s (65/76
studies, 86%); the 11 remaining articles detailed a flow rate
ranging from 2 to 5mL/s. Thirty-five out of 84 (42%) articles
for a total 8734/14012 patients (62%) also mentioned the
use of additional post-contrast saline flush or “bolus chaser,”
19 of them (54%, for a total 4477/8734 patients, 51%) like-
wise detailing a saline amount ranging from 10 to 30mL.
Of 69 studies detailing the tube voltage of both low- and
high-energy acquisitions, all but one (99%) acquired low-
energy images between 26 and 33.2 kVp, which is the peak
kilovoltage threshold of iodine, while all 69 acquired high-
energy images well above this threshold, i.e. between 44
and 50 kVp. The anode/filter combination was reported
Fig. 1 Flowchart of the study selection and exclusion for articles on contrast-enhanced spectral mammography
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by 42/84 studies. Exposure parameters were unambigu-
ously reported only in one study [10], whereas in 5 early
studies [7, 8, 32, 59, 85], they were manually adjusted ac-
cording to breast thickness and density; thirty-five other
studies declared an automatic regulation of these parame-
ters performed by the mammography unit.
Regarding radiation dose, data were scarcer: even
though 45/84 articles (54%) mentioned this aspect, 17/
45 (31%) did it without exhibiting original information
but reporting observations from previous studies, there-
fore restricting the number of studies with new data to
28/84 (33%). Of these 28 studies, 19 (68%) provided an
average glandular dose (AGD), 3 (16%) of them calculat-
ing it per-patient and ranging 1.5–6.9 mGy [8, 9, 58], 5/
19 (26%) calculating it per-breast ranging 2.19–7.15 mGy
and the remaining 11 (58%) reporting a per-view AGD
ranging from 0.43 [61] to 2.65 mGy [101]. A comparison
with DM was mentioned in 17 studies: only 1 (6%) doc-
umented a dose reduction (− 2%) for CESM compared
to DM [32], while other 16 (94%) reported an increase
in AGD ranging between 6.2% [85] and 100% [77]. How-
ever, it is worth to notice that 3 studies specifically con-
trived to assess CESM radiation doses reported an AGD
increase of 42% [56], 78% [82] and 80% [60].
Fig. 2 Geographic distribution of research groups which published results of clinical applications of contrast-enhanced spectral mammography.
From very light blue to dark blue, the number of groups progressively increases from 1 to 7; grey colour means no publications
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Table 1 Main characteristics of the 84 analysed studies
Author/year Ref. Study
design
Country of
research group
Number
of patients
Mean or
median age
(years)
Contrast
agent type
Concentration
(mgI/mL)
Dose
(mL/kg)
Flow
rate
(mL/s)
Delay after
injection (s)
Total
exam
time
Houben 2019 [22] R The Netherlands 147 61 Iopromide 300 1.5 3 120
Barra 2018 [40] P mono Brazil 33 45 Iohexol 300 1.5 3 120 B
Bicchierai 2018 [93] R Italy 40 50 Iopromide 370 1.5 3 120 B
Danala 2018 [69] R USA 111 Iohexol 350 1.5 3 120 B
Deng 2018 [78] R Taiwan 141 48 Iohexol 350 1.5 3 120 B
Helal 2018 [25] P mono Egypt 300 54 Iohexol 300 1.5 3 120 B
Kim 2018 [87] P mono South Korea 84 51 Iohexol 350 1.5 2 120 B
Klang 2018 [88] R Israel 953 51 Iopamidol 370 1.5 3 120 B
Łuczyńska 2018 [36] R Poland 82 57 Iopromide 370 1.5 3 120 B
Moustafa 2018 [17] P mono Egypt 160 Iohexol 300 1.5 3 120 B
Navarro 2018 [90] P mono Chile 465 53 Ioversol 320 1.5 B
Patel 2018 (01) [38] P mono USA 65 53 Iohexol 350 1.5 3 120 A
Patel 2018 (02) [34] R USA 50 57 Iohexol 350 1.5 3 120 B
Patel 2018 (03) [23] R USA 30 66 Iohexol 350 1.5 3 120 B
Phillips 2018 [82] R USA 45 53 Iohexol 350 1.5 3 120
Sorin 2018 [92] R Israel 611 54 Iopamidol 370 1.5 3 120 B
Tohamey 2018 [51] P mono Egypt 178 46 Iohexol 300 1.5 3 120 B
Travieso-Aja 2018 [24] R Spain 158 51 1.5 3 120 B
Xing 2018 [84] P mono China 235 51 Iohexol 350 1.5 3 120 B
Barra 2017 [39] R Brazil 11 46 Iohexol 300 1–2 3 120 B
Bhimani 2017 [13] R USA 2303 Iopamidol 370 1.5 2 120 B
Fallenberg 2017 [76] P multi Germany 155 53 Iobitridol 300 1.5 3 120 A
Gluskin 2017 [63] R USA 5 59 Iohexol 350 1.5 3 150–180 A
Helal 2017 (01) [28] P mono Egypt 98 50 Iohexol 300 1.5 3 120 B
Helal 2017 (02) [99] P mono Egypt 30 47 Iohexol 300 1.5 120
Houben 2017 [58] R The Netherlands 839 60 Iopromide 300 1.5 3 120
Iotti 2017 [37] P mono Italy 54 54 Ioversol 350 1.5 120
James 2017 [56] R USA 173 Iohexol 350 1.5 3 120 A
Jochelson 2017 [54] P mono USA 309 51 Iohexol 350 1.5 3 150–180 B
Knogler 2017 [94] P mono Austria 11 58 Iomeprol 400 2 3.5 90
Lee-Felker 2017 [26] R USA 52 50 Iohexol 350 3 120 B
Lewis 2017 [16] R USA 208 Iohexol 350 1.5 3 120 B
Li 2017 [100] R USA 48 56 Iopamidol 370 1.5 1.5–2 B
Mori 2017 [74] P mono Japan 72 48 Iohexol 300 1.5 3 120
Patel 2017 (01) [27] R USA 88 62 Iohexol 350 1.5 3 120 B
Patel 2017 (02) [65] R USA 410 Iohexol 350 1.5 3 120 B
Phillips 2017 [70] P mono USA 38 53 Iohexol 350 1.5 3 120 B
Richter 2017 [62] R Germany 118 58 Iopromide 300 1.5 2–3 120
Saraya 2017 [18] P mono Egypt 34 54 Iohexol 300 1.5 4 C
Savaridas 2017 [75] P mono Australia 66 54 1.5 3 120 B
Sogani 2017 [80] R USA 278 51 Iohexol 350 1.5 3 150 A
Ali-Mucheru 2016 [33] R USA 351 62 Iohexol 350 1.5 3 120 B
Ambicka 2016 [29] R Poland 82 57 Iopromide 370 1.5 3 120 B
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Table 1 Main characteristics of the 84 analysed studies (Continued)
Author/year Ref. Study
design
Country of
research group
Number
of patients
Mean or
median age
(years)
Contrast
agent type
Concentration
(mgI/mL)
Dose
(mL/kg)
Flow
rate
(mL/s)
Delay after
injection (s)
Total
exam
time
Brandan 2016 [77] P mono Mexico 18 51 Ioversol 300 4 60 B
Cheung 2016 (01) [72] R Taiwan 256 48 Iohexol 350 1.5 3 120 A
Cheung 2016 (02) [98] R Taiwan 87 54 Iohexol 350 1.5 3 120 B
Kamal 2016 [95] R Egypt 239 48 Iohexol 300 1.5 3 120 B
Kariyappa 2016 [68] P mono India 44 Iomeprol 350 1.5 3 120 B
Knogler 2016 [83] P mono Austria 15 58 Iomeprol 400 2 3.5 60–90
Lalji 2016 [21] R The Netherlands 199 58 Iopromide 300 1.5 3 120
Łuczyńska 2016 (01) [50] P mono Poland 116 55 Iopromide 370 1.5 3 120 B
Łuczyńska 2016 (02) [67] P mono Poland 193 55 Iopromide 370 1.5 3 120 B
Tardivel 2016 [19] R France 195 56 Iobitridol 300 1.5 3 120 B
Tennant 2016 [15] R UK 99 49
Tsigginou 2016 [89] P mono Greece 216 55 Iopromide 300 1.5 2–3 120 B
Wang 2016 [97] P mono China 68 53 Iohexol 350 1.5 3 120 A
Yagil 2016 [71] R Israel 200 51 Iopamidol 370 1.5 3 120 B
Chou 2015 [14] P mono Taiwan 185 51 Iohexol 300 1.5 2 120 B
Elsaid 2015 [73] P mono Egypt 34 55 Iohexol 300 1.5 3 B
Hobbs 2015 [81] P mono Australia 49 55 Iohexol 350 1.5 3 120 B
Kamal 2015 [79] R Egypt 168 Iohexol 300 1.5 3 120 B
Lobbes 2015 [30] R The Netherlands 87 62 Iopromide 300 1.5 3 120
Łuczyńska 2015 (01) [91] P mono Poland 174 56 Iopromide 370 1.5 3 120 B
Łuczyńska 2015 (02) [53] P mono Poland 102 Iopromide 370 1.5 3 120
Badr 2014 [101] P mono France 75 54 Iohexol 300 1.5 120 B
Blum 2014 [31] P mono Germany 20 57 Iopamidol 300 1.5 3 120
Cheung 2014 [86] R Taiwan 89 48 Iohexol 350 1.5 3 120–180 B
Fallenberg 2014 (01) [85] P mono Germany 118 53 Iobitridol 300 1.5 3 120 B
Fallenberg 2014 (02) [32] P mono Germany 80 54 Iobitridol 300 1.5 3 120 B
Francescone 2014 [66] R USA 88 50
Jeukens 2014 [60] R The Netherlands 47 58 Iopromide 300 1.5 3 120
Lobbes 2014 [20] R The Netherlands 113 57 Iopromide 300 1.5 3 120
Łuczyńska 2014 [35] P mono Poland 152 56 Iopromide 370 1.5 3 120 B
Mokhtar 2014 [57] P mono Egypt 60 Iohexol 300 1.5 120 A
Travieso-Aja 2014 [64] R Spain 136 49 1.5 3 120 B
Hill 2013 [10] R Canada 98 57 Iobitridol 300 1.5 3 120 B
Jochelson 2013 [55] P mono USA 82 50 Iohexol 350 1.5 3 150–300 B
Dromain 2012 [52] P mono France 110 57 Iobitridol 300 1.5 3 120 A
Diekmann 2011 [61] P mono Germany 70 55 Iopromide 370 1 4 60/120/180 A
Dromain 2011 [59] P mono France 120 56 Iobitridol 300 1.5 3 120 A
Dromain 2006 [9] P mono France 20 63 Iohexol 300 3 30 B
Diekmann 2005 [8] P mono Germany 21 Iopromide 370 1 4 60/120/180 A
Jong 2003 [7] P mono Canada 22 Iohexol 300 60 B
Lewin 2003 [96] P mono USA 26 51 Iohexol 350 4–5 150
R retrospective, P mono prospective monocentric, P multi prospective multicentric, A = total exam time < 5min, B = total exam time between 5 and 10 min, C =
total exam time > 10min
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Acquisition protocols
Studies reporting the time interval between contrast
injection and the first image acquisition were 78 out
of 84 (93%), for a total 13244/14012 patients (95%)
and 65 (83%) of them (12278/13244 patients, 93%)
had it fixed at 120 s.
Sixty-six out of 84 articles (79%, 11900/14012 patients,
85%) gave an indication of the acquisition time after con-
trast injection: in 12/66 (18%, 1381/11900 patients, 11.6%),
the exam was completed in less than 5min; in 52/66 (80%,
for total of 10485/11900 patients, 88.1%) between 5 and 10
min, while in 1/66 (2%, 34/11900 patients, 0.3%) the dur-
ation exceeded 10min.
The outline of the image acquisition sequence remains
more variable. Ten out of 84 studies (12%), accounting for
2734 patients (19%) did not clearly describe it and did not
provide a reference to other protocols, while 3/84 (4%,
103/14012 patients, 1%) employed a curtailed and side-
insensitive acquisition sequence. Adherence to standard
but unspecified digital mammography protocols was de-
clared by 29/84 (34%) studies, for total 3741/14012 pa-
tients (27%). The other half of the articles analysed (42/84,
accounting for 7434/14012 patients, 53%) unequivocally
detailed an acquisition sequence. Of these 42 studies, 14
(34%, 2048/7434 patients, 28%) adopted a projection order
that was conventionally agreed upon, while the other 28
(66%, accounting for 5386/7434 patients, 72%) based their
acquisition sequence on the presence of previous suspect
or clearly pathologic findings.
Eighty-four articles came from 38 different research
groups. Subgroup analysis according to research groups
showed that 17 acquisition sequences based on a conven-
tionally agreed projection order were executed in 15 re-
search groups. As described in Fig. 3, the most common
sequence description, reported by 6/17 (35%) institutions,
was MLO - MLO - CC - CC (in order of acquisition),
without any further indication about the first side to be
examined (right or left or side with/without suspicious le-
sion or already diagnosed cancer). The second most com-
mon sequence (4/17, 24%) was CC - CC - MLO - MLO
with the first projection standardised on the right side (in-
dependently of pathology or with suspected pathology).
Among the 22 acquisition sequences (coming from 20
institutions) centred on the presence of previous suspect
or clearly pathologic findings, we found substantial vari-
ability between different orders of acquisition, as shown
in Fig. 4. However, the most common sequence, adopted
by 4/22 (19%) research groups, was 1) CC, suspected
side; 2) CC, non-suspected side; 3) MLO, suspected side;
and 4) MLO, non-suspected side.
Contrast agent adverse reaction rate meta-analysis
Regarding side effects from ICA administration, 48/84 stud-
ies (57%) declared a preventive anamnestic screening for
previous adverse reactions or general contraindications to
ICA administration. Pre-examination tests of renal function
was mentioned in 39/84 studies (46%). Of note, 14/84 stud-
ies (29%) reported 30 adverse reactions out of 14012 pa-
tients, of which 26/30 (87%) were mild reactions limited to
pruritus, hives, “scratchy throat” or other minor skin flush-
ing that resolved promptly even when antihistamines or cor-
ticosteroids were not administered. In 3/30 (10%) cases [54,
58, 87], side effects were of moderate importance with nau-
sea and vomiting, widespread urticaria resolved only after
antihistamines and corticosteroids per os, and dyspnea that
equally responded to oral antihistamine administration.
Only 1/30 (3%) severe adverse reaction, requiring “intensive
care” but resolved after short time, occurred in 14012 pa-
tients (0.007%) [61].
Therefore, the number of adverse reactions related to
ICA administration ranged from 0, reported by 70 (88%)
studies, to a maximum of 6 adverse reactions [14] with a
total of 30 adverse reactions, showing no heterogeneity
(Q = 64, degree of freedom 83, τ = 2.0972, I2 = 0%, p =
0.931). As shown in the forest plot of Fig. 5, using fixed-
effect model, the pooled rate of adverse reactions across
studies was 0.82%, with 0.64% and 1.05% as 95% CI.
Visually inspecting the funnel plot in Fig. 6, risk of
publication bias was found, as confirmed by the Egger
test (p = 0.00028).
Discussion
Our systematic review included 84 articles, accounting
for 14012 patients, reporting the use of CESM in various
settings. The sheer number of studies and, as depicted in
Fig. 7, their increase in the last 3 years (27 studies be-
tween 2003 and December 2015, 57 from January 2016
to January 2019) points out a considerable interest in
this emerging breast imaging modality.
A number of narrative reviews [6, 42, 102–106] favourably
outlined CESM future perspectives in several clinical set-
tings (e.g. recall work-up, pre-operative staging, and moni-
toring the effect of neoadjuvant therapy) as a potential
alternative to MRI.
In the first phase of CESM development, some non-
fixed parameters regarding contrast agent administration
(i.e. contrast agent molecule, concentration, dose, flow
rate, and injection modality) and some acquisition
features (i.e. time between contrast injection and first ac-
quisition, kVp ranges for low- and high-energy acquisi-
tions) gained an international agreement. However, in
the framework of comprehensive optimisation and
standardisation of CESM, large-scale studies are un-
doubtedly needed to address the knowledge gap con-
cerning the choice of technical parameters.
Our data show a consensus among studies (93%) on the
choice of 1.5mL/kg contrast dose administered with a 3
mL/s flow rate (74%) and a less extensive agreement on the
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use of Iohexol (53% of all studies) at a concentration of 350
mg iodine/mL (30% of all studies). However, these parame-
ters have probably been empirically adopted from CT proto-
cols, as the first investigators plainly stated [7], without any
other particular explication or justification. No dose-finding
studies have been published yet.
Similarly, the common use of a power contrast injector
(87% of all studies, with the remaining 13% coming from a
single research group) is assumed from CT and MRI pro-
tocols in which it has been demonstrated to be effective in
obtaining a stable contrast inflow and bolus shape [107–
109]. Moreover, the use of a power injector allows for the
administration of a bolus chaser, reported only in 42% of
all articles, a technical refinement that has shown good re-
sults in CT [110, 111].
Two other points need to be mentioned. The first one
is the correlation between menstrual cycle phase and
background parenchymal enhancement, explored in a
few studies [10, 75, 80] and/or fluctuations of lesion con-
trast uptake. Secondly, since CESM is based on a dual
X-ray exposure, of which the low-energy one has been
demonstrated to be equal to standard DM [66], an in-
crease in radiation dose is expected. However, while pre-
liminary studies estimated a negligible [7] or curtailed
Fig. 3 Graphical summary of conventionally agreed view acquisition orders for contrast-enhanced spectral mammography: CC craniocaudal view,
MLO mediolateral oblique view, L left, R right
Fig. 4 Graphical summary of pathology-oriented view acquisition orders for contrast-enhanced spectral mammography: CC craniocaudal view,
MLO mediolateral oblique view, S suspicious breast, NS not suspicious breast
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Fig. 5 Forest plot of the 84 analysed articles on contrast-enhanced spectral mammography. No heterogeneity was found among studies (I2 = 0%). The
last row shows the pooled rate for adverse reactions arising from iodinated contrast agent administration, calculated using the fixed-effect model
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AGD increase, studies specifically devised to ascertain
CESM effective AGD found a substantial AGD incre-
ment ranging 42–80% [56, 60, 82]. While CESM AGDs
remain under the threshold stated by European guide-
lines for screening mammography [112], further studies
are needed to investigate CESM AGD [56, 82].
Furthermore, we remark the absence of standardised
protocols. This methodological void, especially regarding
the acquisition workflow, represents a threat to reprodu-
cibility and comparison of imaging results. While 98% of
all studies reporting the total examination time com-
pleted the examination before 10 min from contrast ad-
ministration, and while some studies presented evidence
on the irrelevance of the acquisition order [55, 64], there
are no studies comparing different approaches.
The pooled rate of adverse reactions to ICA adminis-
tration was 0.82% (0.64–1.05% 95% CI) with a total of 30
adverse reactions in 14012 patients, a rate similar to that
reported for CT 0.6% [113] in 84928 adult patients or
0.7% [114] in 29508 patients (given Iopromide, which is
also used for CESM). Particularly, considering only se-
vere adverse reactions in CT, Wang et al. [113] reported
11/84928 (0.0129%) reactions, as well as Mortelé et al.
[114] 4/29508 (0.0135%). These rates seem to be higher
than that found in our meta-analysis 1/14012 (0.007%), a
comparison to consider with caution due to the nature
Fig. 6 Funnel plot showing risk of publication bias in articles on contrast-enhanced spectral mammography, confirmed by the Egger test (p < 0.001)
Fig. 7 Graphic showing the number of articles published per year regarding contrast-enhanced spectral mammography
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of rare events such as severe reactions to ICA. One as-
pect to consider is the different profile of patients under-
going CESM compared to those requiring contrast-
enhanced CT, the former being that of basically
“healthy” subjects, the latter implying the possibility of
relevant disease, including also serious emergency
conditions.
This review has limitations. Patient data are probably
shared and duplicate among some studies from the same
research group. This has been shown to negatively impact
on review quality [115, 116] and could only be prevented
via individual patient data sharing [117]. However, for
technical aspects of this systematic review, our choice to
evaluate study groups rather than single articles should
have mitigated this bias. Conversely, our pooled rate of ad-
verse reactions could be underestimated.
In conclusion, our review shows that CESM is un-
evenly performed across different centres, in terms of
contrast agent type and concentration and order of view
acquisition. However, most research groups performed
CESM using a contrast dose of 1.5 mL/kg, factory-set
kVp ranges for low- and high-energy acquisitions, begin-
ning image acquisition after 120 s from contrast agent
injection and completing the examination within 10min.
Further studies are needed to investigate the role of
background parenchymal enhancement and to harvest
data that can firmly back up subsequent technical guide-
lines and consensus statements for standardised CESM
protocols.
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